Iovance Biotherapeutics’s Amtagvi is now the first FDA-approved treatment based on type of cell called a tumor-infiltrating lymphocyte. The regulatory nod in advanced melanoma also makes Amtagvi the first cell therapy approved for treating a solid tumor.
Replimune’s lead therapeutic candidate did not meet the two main goals of a study intended to support an FDA submission in cutaneous squamous cell carcinoma. But Replimune’s therapy, an oncolytic virus, has better data in melanoma, and the company plans a 2024 FDA submission in this skin cancer.
The future looks bright for the integrated specialty pharmacy model – for health systems, providers, and most importantly, for patients.
Bristol Myers Squibb’s Opdualag has been approved by the FDA, a first for a drug that goes after a new cancer target called LAG-3. The drug is approved for advanced melanoma as part of a combination treatment that includes the already approved BMS cancer immunotherapy Opdivo.
Bristol Myers Squibb bet more than $1.8 billion that Nektar Therapeutics’ drug could be combined with the pharma giant’s Opdivo to expand the reach of that drug to more patients. The drug combination has failed its first Phase 3 in advanced melanoma; separate studies in kidney and bladder cancers are ongoing.
Bristol Myers Squibb reported Phase 3 data that show its experimental cancer immunotherapy relatlimab, combined with the company's blockbuster drug Opdivo, was better at stopping melanoma from progressing. BMS will present the data at the upcoming annual meeting of the American Society of Clinical Oncology.
Array markets a two-drug combination for melanoma and recently announced positive data for the the drugs, Braftovi and Mektovi, in colorectal cancer.
Hear executives from Quantum Health, Surescripts, EY, Clinical Architecture and Personify Health share their views on digital transformation in healthcare.
Only time will tell if a larger Phase III study will confirm data on a few dozen patients, but the two-drug combination appears to produce a higher complete response rate than than an existing doublet combination, without the associated toxicity.
SkinIO, a Chicago-based startup founded by Dr. Jean-Christophe Lapiere and Kyoko Crawford, uses technology to enable patients to monitor their skin health over time.
Four recent engineering graduates from McMaster University, near Toronto, built a device to detect melanoma that measures the temperature differences between melanoma and normal tissue.
Former President Jimmy Carter has been informed that cancer has now spread to his brain.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
DermTech has a biopsy-free approach to test for melanoma - using an adhesive patch to collect skin cells and test if the RNA expression is consistent with cancer.
In order to fuel sales of its cancer diagnostics, Texas startup Castle Biosciences just raised the first, $11.7 million tranche of a $20 million Series D.
People are increasing their risk of melanoma by applying sunscreen to their bodies in patterns after the uncovered parts burn from the sun. #Sunburnart is trending on Twitter and Instagram.
Wearable devices are not just for tracking fitness and overall health. Some are providing much more specific information and recommendations.
San Diego skin cancer diagnostics startup DermTech is developing gene classifiers and expression tests to help more accurately screen for dermatologic issues. It just raised $2.4 million to do so, according to a regulatory filing – an interesting funding notice, given its announcement last year that it was readying for – and then withdrawing – a $25 […]